Information Provided By:
Fly News Breaks for January 19, 2017
KITE, BLFS
Jan 19, 2017 | 08:14 EDT
Maxim analyst Gabrielle Zhou started BioLife Solutions (BLFS) with a Buy rating and $3 price target, saying that its biopreservation media products for cell therapy have advantages over competing media products. Kite Pharma's (KITE) KTE-C19 could be approved in 2017, which would be a milestone for the cell therapy space and a catalyst for BioLife, Zhou tells investors.
News For BLFS;KITE From the Last 2 Days
There are no results for your query BLFS;KITE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.